Hernandez-Hidalgo N, Cortes G, Ortega-Anaya K, Varela H. Fibroblast activation protein inhibitors positron emission tomography/computed tomography: Review of the literature. World J Meta-Anal 2024; 12(4): 95755 [DOI: 10.13105/wjma.v12.i4.95755]
Corresponding Author of This Article
Nathalie Hernandez-Hidalgo, MD, Academic Research, Doctor, Department of Nuclear Medicine, Instituto Nacional de Cancerologia, Cl.1#9-85, Bogota 111321, Colombia. nathaliehh2809@gmail.com
Research Domain of This Article
Nuclear Science & Technology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nathalie Hernandez-Hidalgo, Gerardo Cortes, Humberto Varela, Department of Nuclear Medicine, Instituto Nacional de Cancerologia, Bogota 111321, Colombia
Klissman Ortega-Anaya, Department of Nuclear Medicine, Fundacion Universitaria Sanitas, Bogota 111321, Colombia
Co-first authors: Nathalie Hernandez-Hidalgo and Gerardo Cortes.
Author contributions: Hernandez-Hidalgo N designed the research study; Hernandez-Hidalgo N, Cortes G, Ortega-Anaya K, and Varela H carried out the literature search and subsequent preparation of the manuscript; Hernandez-Hidalgo N, Cortes G, and Ortega-Anaya K analyzed the data and wrote the manuscript; Hernandez-Hidalgo N made Figures 1 and 2; All authors have read and approved the final manuscript.
Conflict-of-interest statement: We don't have any conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nathalie Hernandez-Hidalgo, MD, Academic Research, Doctor, Department of Nuclear Medicine, Instituto Nacional de Cancerologia, Cl.1#9-85, Bogota 111321, Colombia. nathaliehh2809@gmail.com
Received: April 17, 2024 Revised: September 7, 2024 Accepted: September 30, 2024 Published online: December 18, 2024 Processing time: 238 Days and 17.2 Hours
Core Tip
Core Tip: Fibroblast activation protein inhibitors (FAPI) has been a protagonist in the most recent research in the field of nuclear medicine and oncology, demonstrating surprising diagnostic versatility with a dizzying rise, due to its successful labeling with radioisotopes (Ga68 and F18). In the comparative clinical studies that have been carried out to date, it appears that FAPI is superior to fluorodeoxyglucose in oncological diagnostic performance, according to certain advantages it has, mainly related to a better lesion-to-background ratio, lower radiation dose, non-dependence on glucose level or preparatory diet, low brain uptake and its promising use as a theragnostic. FAPI positron emission tomography/computed tomography constitutes a great challenge to address for nuclear medicine and current oncology, which is approaching our present by leaps and bounds, possibly marking a new route in the approach and treatment of oncological diseases.
